Breast cancer

The PBS subsidises lapatinib, pertuzumab, trastuzumab and trastuzumab emtansine for patients with breast cancer.

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with lapatinib, pertuzumab, trastuzumab and trastuzumab emtansine under the National Health Act 1953, section 85 and 100 for patients with breast cancer.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines restrictions for prescribing lapatinib, pertuzumab, trastuzumab and trastuzumab emtansine.

Trastuzumab

All PBS subsidised treatment with trastuzumab is Authority Required (Streamlined) and doesn’t require prior authority approval from us for listed quantities and repeats.

Authority applications

Early HER2 positive breast cancer

Applying for initial treatment

Apply for initial authority approval to prescribe PBS subsidised trastuzumab emtansine to treat early HER2 positive breast cancer in writing and either:

All written applications must include the completed:

Applying for continuing treatment

Applications for continuing authority approval to prescribe PBS subsidised trastuzumab emtansine to treat early HER2 positive breast cancer can be made either:

Metastatic (Stage IV) HER2 positive breast cancer

Applying for initial treatment

Apply for initial authority approval to prescribe PBS subsidised lapatinib, pertuzumab and trastuzumab emtansine to treat metastatic (Stage IV) HER2 positive breast cancer in writing and either:

All written applications must include the completed:

Applying for continuing treatment

Applications for continuing authority approval to prescribe PBS subsidised pertuzumab and trastuzumab emtansine to treat metastatic (Stage IV) HER2 positive breast cancer can be made either:

Continuing PBS subsidised treatment with lapatinib is Authority Required (Streamlined). It doesn't need prior authority approval from us for listed quantities and repeats.

Further information

Call the PBS Complex Drugs Programs enquiry line for further information.

Page last updated: 1 May 2021